Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...8889909192939495969798...123124»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Clinical, Journal:  Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. (Pubmed Central) -  Feb 25, 2021   
    Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. The combination therapy had a manageable toxicity profile.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    [VIRTUAL] Updated Synopsis on Current Medical Therapies for Hepatocellular Carcinoma (HCC) () -  Feb 24, 2021 - Abstract #SIR2021SIR_921;    
    The effect of these medications on IR therapies is critical.Clinical Findings/Procedure Details: The Exhibit will comprehensively review the medical therapies available to treat HCC including multi-receptor tyrosine kinase inhibitors (sorafenib, regorafenib, lenvatinib and cabozantinib); monoclonal antibodies (ramucirumab and bevacizumab) which target vascular endothelial growth factor (VEGF); and immunotherapies (nivolumab, atezolizumab, pembrolizumab)...Finally, results on combining medical therapy with locoregional therapy will be covered including the TACTICS trial (which showed a benefit from combining chemoembolization and sorafenib).Conclusion and/or Teaching Points: To be an effective Interventional Radiologist treating HCC requires an up to date grasp of medical therapies, their benefits, adverse effects and limitations since these medical therapies are being proffered as adjunctive and/or combination therapies and sometimes even as alternative therapies. This Exhibit reviews those medical therapies.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Journal, Real-World Evidence:  Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States. (Pubmed Central) -  Feb 23, 2021   
    LEAP-012 will elucidate the clinical benefit of adding lenvatinib plus pembrolizumab to the current standard of care TACE for patients with intermediate-stage HCC not amenable to curative treatment. In this first real-world examination of clinical effectiveness of 1L lenvatinib and subsequent therapy among patients in the US, the results demonstrated that treatment with 1L lenvatinib followed by another 2L therapy may deliver a clinical benefit, thus allowing a number of potential 2L options following 1L lenvatinib for patients with RAI-r DTC.
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis (clinicaltrials.gov) -  Feb 23, 2021   
    P2,  N=25, Recruiting, 
    Lenvatinib at 14 mg appears to be effective, fast and well tolerated. Trial completion date: Dec 2020 --> Apr 2021 | Trial primary completion date: Nov 2020 --> Apr 2021
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) -  Feb 18, 2021   
    P4,  N=50, Active, not recruiting, 
    Finally, we focus on the novel approaches, future perspectives and potential challenges about the combination of TKIs and ICIs. Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Jun 2020 --> Mar 2021